Literature DB >> 23037817

Poor cognitive outcome in shunt-responsive idiopathic normal pressure hydrocephalus.

Anne M Koivisto1, Irina Alafuzoff, Sakari Savolainen, Anna Sutela, Jaana Rummukainen, Mitja Kurki, Juha E Jääskeläinen, Hilkka Soininen, Jaakko Rinne, Ville Leinonen.   

Abstract

BACKGROUND: Idiopathic normal pressure hydrocephalus (iNPH) causes cognitive decline that can be alleviated by shunting, but long-term outcome studies are scarce.
OBJECTIVE: To elucidate the long-term cognitive condition of shunt-responsive iNPH patients.
METHODS: The follow-up data (Kuopio University Hospital NPH Registry) of 146 patients diagnosed with iNPH by clinical and radiological examination, 24-hour intraventricular pressure monitoring, frontal cortical biopsy, and response to the shunt were analyzed for signs of dementia. The Diagnostic and Statistical Manual for Mental Disorders, Fourth Edition, and specified memory disorder criteria were used. Median follow-up was 4.8 years.
RESULTS: At the end of follow-up, 117 (80%) of the 146 iNPH patients had cognitive decline and 67 (46%) had clinical dementia. The most common clinical diagnoses were Alzheimer disease and vascular dementia. In multivariate analysis of the 146 iNPH patients, memory deficit as a first symptom before shunt (odds ratio [OR] 18.3; 95% confidence interval [CI] 1.9-175), male sex (OR 3.29; 95% CI 1.11-9.73), age (OR 1.17 year; 95% CI 1.07-1.28), and follow-up time (OR 1.20 year; 95% CI 1.02-1.40) predicted dementia. Interestingly, 8 (5%) iNPH patients had dementia without any signs of other neurodegenerative diseases in clinical, neuroradiological, or brain biopsy evaluation. These patients initially presented a full triad of symptoms, with gait disturbance being the most frequent initial symptom followed by deterioration in cognition.
CONCLUSION: The novel findings were (a) a significant risk of dementia in iNPH initially responsive to cerebrospinal fluid shunt, (b) cognitive impairment most commonly due to iNPH-related dementia followed by concurrent degenerative brain disease, and (c) a subgroup with dementia related to iNPH without comorbidities.

Entities:  

Mesh:

Year:  2013        PMID: 23037817     DOI: 10.1227/NEU.0b013e31827414b3

Source DB:  PubMed          Journal:  Neurosurgery        ISSN: 0148-396X            Impact factor:   4.654


  19 in total

Review 1.  A review of cognitive impairment and differential diagnosis in idiopathic normal pressure hydrocephalus.

Authors:  Marta Picascia; Roberta Zangaglia; Sara Bernini; Brigida Minafra; Elena Sinforiani; Claudio Pacchetti
Journal:  Funct Neurol       Date:  2015 Oct-Dec

2.  Comparison of Assessment for Shunting with Infusion Studies Versus Extended Lumbar Drainage in Suspected Normal Pressure Hydrocephalus.

Authors:  Virginia Levrini; Matthew Garnett; Eva Nabbanja; Marek Czosnyka; Zofia H Czosnyka; Afroditi D Lalou
Journal:  Acta Neurochir Suppl       Date:  2021

3.  Neuropsychological assessments and cognitive profile mostly associated with shunt surgery in idiopathic normal pressure hydrocephalus patients: diagnostic and predictive parameters and practical implications.

Authors:  Mor Nimni; Penina Weiss; Chen Cohen; Yosef Laviv
Journal:  Acta Neurochir (Wien)       Date:  2021-09-03       Impact factor: 2.216

4.  Delayed clearance of cerebrospinal fluid tracer from entorhinal cortex in idiopathic normal pressure hydrocephalus: A glymphatic magnetic resonance imaging study.

Authors:  Per K Eide; Geir Ringstad
Journal:  J Cereb Blood Flow Metab       Date:  2018-02-27       Impact factor: 6.200

5.  Leucine-rich α2-glycoprotein is a novel biomarker of neurodegenerative disease in human cerebrospinal fluid and causes neurodegeneration in mouse cerebral cortex.

Authors:  Masakazu Miyajima; Madoka Nakajima; Yumiko Motoi; Masao Moriya; Hidenori Sugano; Ikuko Ogino; Eri Nakamura; Norihiro Tada; Miyuki Kunichika; Hajime Arai
Journal:  PLoS One       Date:  2013-09-18       Impact factor: 3.240

6.  Cerebrospinal fluid biomarker and brain biopsy findings in idiopathic normal pressure hydrocephalus.

Authors:  Okko T Pyykkö; Miikka Lumela; Jaana Rummukainen; Ossi Nerg; Toni T Seppälä; Sanna-Kaisa Herukka; Anne M Koivisto; Irina Alafuzoff; Lakshman Puli; Sakari Savolainen; Hilkka Soininen; Juha E Jääskeläinen; Mikko Hiltunen; Henrik Zetterberg; Ville Leinonen
Journal:  PLoS One       Date:  2014-03-17       Impact factor: 3.240

7.  Diagnostic effectiveness of quantitative [¹⁸F]flutemetamol PET imaging for detection of fibrillar amyloid β using cortical biopsy histopathology as the standard of truth in subjects with idiopathic normal pressure hydrocephalus.

Authors:  Ville Leinonen; Juha O Rinne; Dean F Wong; David A Wolk; John Q Trojanowski; Paul F Sherwin; Adrian Smith; Kerstin Heurling; Mandy Su; Igor D Grachev
Journal:  Acta Neuropathol Commun       Date:  2014-04-22       Impact factor: 7.801

8.  Noninvasive prediction of shunt operation outcome in idiopathic normal pressure hydrocephalus.

Authors:  Yasunori Aoki; Hiroaki Kazui; Toshihisa Tanaka; Ryouhei Ishii; Tamiki Wada; Shunichiro Ikeda; Masahiro Hata; Leonides Canuet; Themistoklis Katsimichas; Toshimitsu Musha; Haruyasu Matsuzaki; Kaoru Imajo; Hideki Kanemoto; Tetsuhiko Yoshida; Keiko Nomura; Kenji Yoshiyama; Masao Iwase; Masatoshi Takeda
Journal:  Sci Rep       Date:  2015-01-14       Impact factor: 4.379

9.  EEG and Neuronal Activity Topography analysis can predict effectiveness of shunt operation in idiopathic normal pressure hydrocephalus patients.

Authors:  Yasunori Aoki; Hiroaki Kazui; Toshihisa Tanaka; Ryouhei Ishii; Tamiki Wada; Shunichiro Ikeda; Masahiro Hata; Leonides Canuet; Toshimitsu Musha; Haruyasu Matsuzaki; Kaoru Imajo; Kenji Yoshiyama; Tetsuhiko Yoshida; Yoshiro Shimizu; Keiko Nomura; Masao Iwase; Masatoshi Takeda
Journal:  Neuroimage Clin       Date:  2013-10-19       Impact factor: 4.881

10.  Evaluation of coexistence of Alzheimer's disease in idiopathic normal pressure hydrocephalus using ELISA analyses for CSF biomarkers.

Authors:  Tae Sung Lim; Jun Young Choi; Sun Ah Park; Young Chul Youn; Hyun Young Lee; Byung Gon Kim; In Soo Joo; Kyoon Huh; So Young Moon
Journal:  BMC Neurol       Date:  2014-04-01       Impact factor: 2.474

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.